SB465
Inexpedient to Legislate (House)classifying xylazine as a schedule III controlled drug.
Status
Hearing
No upcoming hearing scheduled.
Testimony
26 total submissions
Bill Docket
Inexpedient to Legislate: MA VV 04/23/2026 HJ 11
HouseApril 23, 2026
Minority Committee Report: Ought to Pass
HouseApril 15, 2026
Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)
HouseApril 15, 2026
Executive Session: 04/14/2026 01:00 pm GP 153
HouseApril 08, 2026
Full Committee Work Session: 04/07/2026 01:00 pm GP 153
HouseApril 01, 2026
Public Hearing: 03/31/2026 01:30 pm GP 153
HouseMarch 18, 2026
Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8
HouseMarch 16, 2026
Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5
SenateFebruary 24, 2026
Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5
SenateFebruary 24, 2026
Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8
SenateFebruary 20, 2026
Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A
SenateFebruary 05, 2026
Introduced 01/07/2026 and Referred to Judiciary; SJ 1
SenateNovember 21, 2025